FDA Determines Regulatory Review Period for JUBLIA Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for JUBLIA, a human drug product, as required by law after receiving a patent extension application from the U.S. Patent and Trademark Office (USPTO).